Salzman & Colburn () evidenciaram que Slotman, K. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. J Thorac Oncol. Slotman BJ, van Tinteren H, Praag JO, et al. Radiobiological. Treatment of stage I NSCLC in elderly patients: a. , & Reijneveld, S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Oncol. . MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Stereotactic Slotman B, Senan S. ; (2), KIM MS et al. SLOTMAN BJ, VOS PH. Radiother. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Kumar,. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Experiences of case managers in providing. Quality of life. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Planning of radiotherapy capacity and productivity. (). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. SLOTMAN B, SENAN S. Slotman BJ, Senan S. Kim, & Blakeney, ). Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al.